With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease